JERUSALEM, Israel, May 11 /PRNewswire/ -- Intec Pharma, an oral drug delivery company specializing in gastric retention, today announced the appointment of Efi Cohen Arazi, as Chief Executive Officer. Mr. Cohen Arazi will be responsible for setting and implementing Intec's global strategy, based on the company's proprietary gastric retention controlled released product platform.
Intec is the developer of the breakthrough Accordion Pill technology that significantly extends the residence-time of pharmaceuticals in the stomach and overcomes many of the problems associated with the Narrow Absorption Window. Intec plans to partner with pharma and biotech companies to improve pipeline productivity and better manage product life cycle. In addition, Intec plans to develop its own drug development portfolio.
"Efi brings to Intec a wealth of international management experience gained over 20 years in the biopharmaceutical industry," said Zvi Joseph, Intec's Chairman. "I am confident he will prove a strong leader who can build upon the unparalleled gastric retention solution Intec has to offer the industry."
Mr. Cohen Arazi joins Intec from Amgen in the US where he worked for the last three years. At Amgen he was respectively Vice-President, Corporate Manufacturing, Head of Contract Manufacturing and Site Head, Thousand Oaks. In his capacity as Head of the Contract Manufacturing Operations at Amgen, he established and led several strategic partnerships for development and manufacturing of small molecules and biopharmaceuticals.
Prior to working with Amgen, Mr. Cohen Arazi was the Head of Operations at Immunex, where he developed and implemented strategies to ensure supply of Enbrel(R) the company's blockbuster drug. Mr. Cohen Arazi worked for more than 12 years in a variety of leadership positions with Serono in Switzerland and Israel.
"I am very excited to join Intec Pharma and to have a unique opportunity to address the unmet need for a true gastric retention system in the biopharma industry. The prospect of finding innovative controlled release solutions through utilizing the scientific findings and talented personnel at Intec were the key reasons I accepted the challenge. I believe Intec's unique mix of proprietary technology and implementation capabilities will enable the company to become a leading player in the controlled release field."
For more info visit http://www.intecpharma.com/
Stanley Fass, +972-2-586-4657 ext. 104
Etti Lavian, +972-2-586-4657 ext. 101
CONTACT: Intec Pharma, Sanley Fass, Tel: +972-2-586-4657 ext. 104, EttiLavian, Tel: +972-2-586-4657 ext. 101